logo

North America Oral Anti-Diabetic Drug Market Size (2024 - 2029)

The North America Oral Anti-Diabetic Drug Market is anticipated to experience growth over the forecast period, driven by factors such as the increasing prevalence of diabetes and the impact of the COVID-19 pandemic. The pandemic highlighted the vulnerabilities of diabetes patients, leading to a greater reliance on diabetic medications to manage blood glucose levels. Additionally, the shift towards remote healthcare and the easing of regulatory barriers have further supported market expansion. These elements collectively contribute to the anticipated growth in the market size during the specified period.

Home Market Analysis Healthcare Research Pharmaceuticals Research Disease Specific Drugs Research Chronic Disorder Drugs Research Diabetes Care Drugs Research North America Oral Anti-Diabetic Drug Market Market Size

Market Size of North America Oral Anti-Diabetic Drug Industry

North America Oral Anti-Diabetic Drug Market Summary
Study Period 2019 - 2029
Base Year For Estimation 2023
Forecast Data Period 2024 - 2029
Market Size (2024) USD 18.76 Billion
Market Size (2029) USD 23.60 Billion
CAGR (2024 - 2029) 4.70 %

Major Players

North America Oral Anti-Diabetic Drug Market Major Players

*Disclaimer: Major Players sorted in no particular order

North America Oral Anti-Diabetic Drug Market Analysis

The North America Oral Anti-Diabetic Drug Market size is estimated at USD 18.76 billion in 2024, and is expected to reach USD 23.60 billion by 2029, growing at a CAGR of 4.70% during the forecast period (2024-2029).

The North American oral anti-diabetic drug market is anticipated to record significant growth due to the increasing prevalence of diabetes and the rising preference for oral medications. Given the myriad health issues associated with diabetes, patients must maintain their blood glucose levels throughout the day.

The region's escalating diabetes prevalence underscores the growing demand for oral anti-diabetic drugs. For instance, CDC data from November 2023 revealed that the United States alone had about 38.4 million diabetes patients, with an additional 97.6 million adults aged 18 or older classified as prediabetic. The statistics highlighted the region's pressing need for oral anti-diabetic medications, setting the stage for significant market expansion.

A notable shift toward oral medications for diabetes treatment is reshaping the market landscape. A study from PLOS ONE in July 2023 highlighted Mexico's consistent trend of favoring drug-based treatments for type 2 diabetes mellitus. Aligning clinical practices with current guidelines not only steers clear of inappropriate prescriptions but also enhances medical care, potentially leading to better glycemic control for these patients.

The North American oral anti-diabetic drug market is poised for substantial growth, driven by the high diabetics prevalence and the growing adoption of oral medications. As healthcare practices continue to evolve, the demand for effective diabetes management solutions will likely sustain this upward trajectory.

North America Oral Anti-Diabetic Drug Industry Segmentation

Antihyperglycemic medications are taken orally to lower blood glucose levels. They are frequently employed in the management of type 2 diabetes.

The North American oral anti-diabetic drug market is segmented by drugs, patient type, and geography. By drug, the market is segmented by biguanides, alpha-glucosidase inhibitors, dopamine-d2 receptor agonists, sodium-glucose cotransport-2 (SGLT-2) inhibitor, dipeptidyl peptidase-4 (DPP-4) inhibitors, sulfonylureas, and meglitinides. By patient type, the market is segmented into adults, geriatric, and pediatric. By geography, the market is segmented into the United States, Canada, and Mexico. The report offers the value (USD) for all the above segments.

By Drug Types
Biguanides
Alpha-Glucosidase Inhibitors
Dopamine D2 Receptor Agonist
SGLT-2 Inhibitors
Invokana (Canagliflozin)
Jardiance (Empagliflozin)
Farxiga/Forxiga (Dapagliflozin)
Suglat (Ipragliflozin)
DPP-4 Inhibitors
Onglyza (Saxagliptin)
Tradjenta (Linagliptin)
Vipidia/Nesina (Alogliptin)
Galvus (Vildagliptin)
Sulfonylureas
Meglitinides
By Patient Type
Adults
Geriatric
Pediatric
Geography
United States
Canada
Mexico
Need A Different Region Or Segment?
Customize Now

North America Oral Anti-Diabetic Drug Market Size Summary

The North American oral anti-diabetic drug market is poised for significant growth, driven by the increasing prevalence of diabetes and the rising demand for effective treatment options. The market is characterized by a robust pipeline of innovative medications and a strong focus on research and development by major pharmaceutical companies. The COVID-19 pandemic has further underscored the importance of diabetes management, as individuals with diabetes are at a higher risk of severe complications from the virus. This has led to an increased emphasis on remote healthcare solutions and the removal of regulatory barriers, facilitating better access to diabetes medications. The market is dominated by key players such as Eli Lilly, AstraZeneca, Sanofi, and Janssen Pharmaceuticals, who are actively engaged in expanding their product offerings and enhancing their market presence.

The market landscape is also shaped by the widespread use of metformin, a first-line treatment for type 2 diabetes, known for its efficacy, safety, and cost-effectiveness. Metformin's broad acceptance and prescription rate highlight its critical role in diabetes management. Additionally, the introduction of new drug classes, such as sodium-glucose cotransporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors, has expanded treatment options for patients. The market is further supported by initiatives to make diabetes medications more affordable through discounts and insurance coverage. As the diabetes population in North America continues to grow, the demand for oral anti-diabetic drugs is expected to rise, driving market expansion over the forecast period.

Explore More

North America Oral Anti-Diabetic Drug Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Market Drivers

      1. 1.2.1 Rising Prevalence Of Diabetes

      2. 1.2.2 Reimbursement Policies For Diabetes Oral Medications

    3. 1.3 Market Restraints

      1. 1.3.1 Stringent Regulatory Requirements For Product Approval

    4. 1.4 Porter's Five Forces Analysis

      1. 1.4.1 Bargaining Power of Suppliers

      2. 1.4.2 Bargaining Power of Consumers

      3. 1.4.3 Threat of New Entrants

      4. 1.4.4 Threat of Substitute Products and Services

      5. 1.4.5 Intensity of Competitive Rivalry

  2. 2. MARKET SEGMENTATION (Market Size in Values - USD)

    1. 2.1 By Drug Types

      1. 2.1.1 Biguanides

      2. 2.1.2 Alpha-Glucosidase Inhibitors

      3. 2.1.3 Dopamine D2 Receptor Agonist

      4. 2.1.4 SGLT-2 Inhibitors

        1. 2.1.4.1 Invokana (Canagliflozin)

        2. 2.1.4.2 Jardiance (Empagliflozin)

        3. 2.1.4.3 Farxiga/Forxiga (Dapagliflozin)

        4. 2.1.4.4 Suglat (Ipragliflozin)

      5. 2.1.5 DPP-4 Inhibitors

        1. 2.1.5.1 Onglyza (Saxagliptin)

        2. 2.1.5.2 Tradjenta (Linagliptin)

        3. 2.1.5.3 Vipidia/Nesina (Alogliptin)

        4. 2.1.5.4 Galvus (Vildagliptin)

      6. 2.1.6 Sulfonylureas

      7. 2.1.7 Meglitinides

    2. 2.2 By Patient Type

      1. 2.2.1 Adults

      2. 2.2.2 Geriatric

      3. 2.2.3 Pediatric

    3. 2.3 Geography

      1. 2.3.1 United States

      2. 2.3.2 Canada

      3. 2.3.3 Mexico

North America Oral Anti-Diabetic Drug Market Size FAQs

The North America Oral Anti-Diabetic Drug Market size is expected to reach USD 18.76 billion in 2024 and grow at a CAGR of 4.70% to reach USD 23.60 billion by 2029.

In 2024, the North America Oral Anti-Diabetic Drug Market size is expected to reach USD 18.76 billion.

North America Oral Anti-Diabetic Drug Market Report Snapshots

North America Oral Anti-Diabetic Drug Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)